Showing results (1711-1720 of 1,742) with videos related to

Sort By:
Pageof 175
Molecular Psychiatry|January 13, 2023
Genetic, individual, and familial risk correlates of brain network controllability in major depressive disorderTim Hahn, Nils R Winter, Jan Ernsting, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 12, 2017
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Melissa Alsina, et al.
Nature|November 28, 2024
Cancer cells impair monocyte-mediated T cell stimulation to evade immunityAnais Elewaut, Guillem Estivill, Felix Bayerl, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 11, 2015
Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in OncologyKenneth C Anderson, Melissa Alsina, Djordje Atanackovic, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 4, 2018
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018Shaji K Kumar, Natalie S Callander, Melissa Alsina, et al.
The Lancet. Haematology|September 14, 2023
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trialPeter M Voorhees, Douglas W Sborov, Jacob Laubach, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 10, 2016
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016Kenneth C Anderson, Melissa Alsina, Djordje Atanackovic, et al.
Science Advances|January 5, 2022
An uncertainty-aware, shareable, and transparent neural network architecture for brain-age modelingTim Hahn, Jan Ernsting, Nils R Winter, et al.
Blood|April 24, 2020
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trialPeter M Voorhees, Jonathan L Kaufman, Jacob Laubach, et al.
Health Technology Assessment (Winchester, England)|June 2, 2025
Pramipexole in addition to mood stabilisers for treatment-resistant bipolar depression: the PAX-BD randomised double-blind placebo-controlled trialHamish McAllister-Williams, Nicola Goudie, Lumbini Azim, et al.
Pageof 175